Biomaterials suitable for use as drug eluting, magnetic resonance imaging detectable implants for vascular occlusion
Biomaterials suitable for use as drug eluting, Magnetic Resonance Imaging (“MRI”) detectable implants for vascular occlusion are provided, as are methods of producing such biomaterials. Further, methods of treating an individual suffering from a solid tumor are provided.
1. A biomaterial suitable for use as a drug eluting, Magnetic Resonance Imaging (“MRI”) detectable implant for vascular occlusion, comprising:
a copolymer comprising N-[tris-(hydroxymethyl)methyl] acrylamide and vinyl sulfonate;
an iron oxide particle; and
a drug.
2. The biomaterial of claim 1 , wherein the biomaterial is in the form of substantially spherical microspheres.
3. The biomaterial of claim 2 , wherein the microspheres have an average major axis of from about 15 micrometers to about 1000 micrometers.
4. The biomaterial of claim 1 , wherein the biomaterial further comprises N,N-methylene-bis-acrylamide.
5. The biomaterial of claim 1 , wherein the copolymer further comprises a crosslinking agent.
6. The biomaterial of claim 1 , wherein the drug is a chemotherapeutic drug.
7. The biomaterial of claim 6 , wherein the drug is at least one of doxorubicin or irinotecan.
8. The biomaterial of claim 1 , wherein the biomaterial comprises 5 wt % to 50 wt % of vinyl sulfonate.
9. The biomaterial of claim 2 , wherein the drug is releasably associated with the microsphere.
10. The biomaterial of claim 1 , wherein the iron oxide particle comprises Fe 3 O 4 .
11. The biomaterial of claim 1 , wherein the iron oxide particle comprises colloidal iron.
12. A biomaterial suitable for use as a drug eluting, Magnetic Resonance Imaging (“MRI”) detectable implant for vascular occlusion, comprising:
a copolymer comprising N-[tris-(hydroxymethyl)methyl] acrylamide and 2-carboxyethyl acrylate (“CEA”);
an iron oxide particle; and
a drug.
13. The biomaterial of claim 12 , wherein the biomaterial is in the form of substantially spherical microspheres.
14. The biomaterial of claim 12 , wherein the biomaterial further comprises N,N-methylene-bis-acrylamide.
15. The biomaterial of claim 12 , wherein the copolymer further comprises a crosslinking agent.
16. The biomaterial of claim 12 , wherein the drug is at least one of doxorubicin or irinotecan.
17. The biomaterial of claim 12 , wherein the biomaterial comprises 5 wt % to 50 wt % of CEA.
18. The biomaterial of claim 13 , wherein the drug is releasably associated with the microsphere.
19. The biomaterial of claim 12 , wherein the iron oxide particle comprises Fe 3 O 4 .
20. The biomaterial of claim 12 , wherein the iron oxide particle comprises colloidal iron.